Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Spotlight Review
  • Published:

Spotlight on miRNA in Hematopoiesis

Deregulation of microRNAs in myelodysplastic syndrome

Leukemia volume 26, pages 13–22 (2012)Cite this article

Abstract

Myelodysplastic syndromes (MDSs) consist of a family of hematopoietic stem cell (HSC) disorders characterized by ineffective differentiation of hematopoietic progenitors, bone marrow dysplasia, genetic instability and a propensity to develop acute myeloid leukemia. The development of MDS is poorly understood and therefore, effective treatment options are limited. Recent progress has been made in identifying altered signaling pathways and understanding the HSC defects, which are thought to contribute to the pathogenesis of MDS. Several of these findings have implicated aberrant expression and function of microRNAs (miRNAs). Unique miRNA expression patterns have been identified in MDS patients and modeled in mice to recapitulate features of MDS. Here, we review miRNA expression profiles identified in MDS patients, and describe the association of miRNA expression with MDS subtypes and disease outcome, clinical implications of miRNAs in MDS and deregulation of miRNAs in mouse model systems of MDS.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Corey SJ, Minden MD, Barber DL, Kantarjian H, Wang JC, Schimmer AD . Myelodysplastic syndromes: the complexity of stem-cell diseases. Nat Rev Cancer 2007; 7: 118–129.

    CAS  PubMed  Google Scholar 

  2. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 2079–2088.

    CAS  PubMed  Google Scholar 

  3. Cazzola M, Malcovati L . Prognostic classification and risk assessment in myelodysplastic syndromes. Hematol Oncol Clin North Am 2010; 24: 459–468.

    Article  PubMed  Google Scholar 

  4. Nilsson L, Eden P, Olsson E, Mansson R, Astrand-Grundstrom I, Strombeck B et al. The molecular signature of MDS stem cells supports a stem-cell origin of 5q myelodysplastic syndromes. Blood 2007; 110: 3005–3014.

    Article  CAS  PubMed  Google Scholar 

  5. Nilsson L, Astrand-Grundstrom I, Arvidsson I, Jacobsson B, Hellstrom-Lindberg E, Hast R et al. Isolation and characterization of hematopoietic progenitor/stem cells in 5q-deleted myelodysplastic syndromes: evidence for involvement at the hematopoietic stem cell level. Blood 2000; 96: 2012–2021.

    CAS  PubMed  Google Scholar 

  6. Tiu R, Gondek L, O’Keefe C, Maciejewski JP . Clonality of the stem cell compartment during evolution of myelodysplastic syndromes and other bone marrow failure syndromes. Leukemia 2007; 21: 1648–1657.

    Article  CAS  PubMed  Google Scholar 

  7. Guidetti F, Grazioli S, Capelli F, Marini C, Gallicchio M, De Micheli D et al. Primitive hematopoietic stem cells shows a polyclonal pattern in myelodysplastic syndromes. Haematologica 2004; 89: 21–28.

    PubMed  Google Scholar 

  8. Bartel DP . MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281–297.

    Article  CAS  PubMed  Google Scholar 

  9. Djuranovic S, Nahvi A, Green R . A parsimonious model for gene regulation by miRNAs. Science 2011; 331: 550–553.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Vasudevan S, Tong Y, Steitz JA . Switching from repression to activation: microRNAs can up-regulate translation. Science 2007; 318: 1931–1934.

    Article  CAS  PubMed  Google Scholar 

  11. Khraiwesh B, Arif MA, Seumel GI, Ossowski S, Weigel D, Reski R et al. Transcriptional control of gene expression by microRNAs. Cell 2011; 140: 111–122.

    Article  Google Scholar 

  12. Cissell KA, Deo SK . Trends in microRNA detection. Anal Bioanal Chem 2009; 394: 1109–1116.

    Article  CAS  PubMed  Google Scholar 

  13. Schotte D, Moqadam FA, Lange-Turenhout EA, Chen C, van Ijcken WF, Pieters R et al. Discovery of new microRNAs by small RNAome deep sequencing in childhood acute lymphoblastic leukemia. Leukemia 2011; in press.

  14. Morin RD, O’Connor MD, Griffith M, Kuchenbauer F, Delaney A, Prabhu AL et al. Application of massively parallel sequencing to microRNA profiling and discovery in human embryonic stem cells. Genome Res 2008; 18: 610–621.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Petriv OI, Kuchenbauer F, Delaney AD, Lecault V, White A, Kent D et al. Comprehensive microRNA expression profiling of the hematopoietic hierarchy. Proc Natl Acad Sci USA 2010; 107: 15443–15448.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Guo S, Lu J, Schlanger R, Zhang H, Wang JY, Fox MC et al. MicroRNA miR-125a controls hematopoietic stem cell number. Proc Natl Acad Sci USA 2010; 107: 14229–14234.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Koralov SB, Muljo SA, Galler GR, Krek A, Chakraborty T, Kanellopoulou C et al. Dicer ablation affects antibody diversity and cell survival in the B lymphocyte lineage. Cell 2008; 132: 860–874.

    Article  CAS  PubMed  Google Scholar 

  18. Cobb BS, Hertweck A, Smith J, O’Connor E, Graf D, Cook T et al. A role for Dicer in immune regulation. J Exp Med 2006; 203: 2519–2527.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Navarro F, Lieberman J . Small RNAs guide hematopoietic cell differentiation and function. J Immunol 2010; 184: 5939–5947.

    Article  CAS  PubMed  Google Scholar 

  20. Baltimore D, Boldin MP, O’Connell RM, Rao DS, Taganov KD . MicroRNAs: new regulators of immune cell development and function. Nat Immunol 2008; 9: 839–845.

    Article  CAS  PubMed  Google Scholar 

  21. Georgantas III RW, Hildreth R, Morisot S, Alder J, Liu CG, Heimfeld S et al. CD34+ hematopoietic stem-progenitor cell microRNA expression and function: a circuit diagram of differentiation control. Proc Natl Acad Sci USA 2007; 104: 2750–2755.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Liao R, Sun J, Zhang L, Lou G, Chen M, Zhou D et al. MicroRNAs play a role in the development of human hematopoietic stem cells. J Cell Biochem 2008; 104: 805–817.

    Article  CAS  PubMed  Google Scholar 

  23. Ooi AG, Sahoo D, Adorno M, Wang Y, Weissman IL, Park CY . MicroRNA-125b expands hematopoietic stem cells and enriches for the lymphoid-balanced and lymphoid-biased subsets. Proc Natl Acad Sci USA 2011; 107: 21505–21510.

    Article  Google Scholar 

  24. Merkerova M, Vasikova A, Belickova M, Bruchova H . MicroRNA expression profiles in umbilical cord blood cell lineages. Stem Cells Dev 2010; 19: 17–26.

    Article  CAS  PubMed  Google Scholar 

  25. Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA 2004; 101: 2999–3004.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D et al. MicroRNA expression profiles classify human cancers. Nature 2005; 435: 834–838.

    Article  CAS  PubMed  Google Scholar 

  27. Starczynowski DT, Morin R, McPherson A, Lam J, Chari R, Wegrzyn J et al. Genome-wide identification of human microRNAs located in leukemia-associated genomic alterations. Blood 2011; 117: 595–607.

    Article  CAS  PubMed  Google Scholar 

  28. Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E et al. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2002; 99: 15524–15529.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Cimmino A, Calin GA, Fabbri M, Iorio MV, Ferracin M, Shimizu M et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci USA 2005; 102: 13944–13949.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Garzon R, Volinia S, Liu CG, Fernandez-Cymering C, Palumbo T, Pichiorri F et al. MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. Blood 2008; 111: 3183–3189.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Eyholzer M, Schmid S, Schardt JA, Haefliger S, Mueller BU, Pabst T . Complexity of miR-223 regulation by CEBPA in human AML. Leuk Res 2010; 34: 672–676.

    Article  CAS  PubMed  Google Scholar 

  32. Garzon R, Garofalo M, Martelli MP, Briesewitz R, Wang L, Fernandez-Cymering C et al. Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin. Proc Natl Acad Sci USA 2008; 105: 3945–3950.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Cammarata G, Augugliaro L, Salemi D, Agueli C, La Rosa M, Dagnino L et al. Differential expression of specific microRNA and their targets in acute myeloid leukemia. Am J Hematol 2010; 85: 331–339.

    CAS  PubMed  Google Scholar 

  34. Marcucci G, Radmacher MD, Maharry K, Mrozek K, Ruppert AS, Paschka P et al. MicroRNA expression in cytogenetically normal acute myeloid leukemia. N Engl J Med 2008; 358: 1919–1928.

    Article  CAS  PubMed  Google Scholar 

  35. Hussein K, Theophile K, Busche G, Schlegelberger B, Gohring G, Kreipe H et al. Aberrant microRNA expression pattern in myelodysplastic bone marrow cells. Leuk Res 2010; 34: 1169–1174.

    Article  CAS  PubMed  Google Scholar 

  36. Sokol L, Caceres G, Volinia S, Alder H, Nuovo GJ, Liu CG et al. Identification of a risk dependent microRNA expression signature in myelodysplastic syndromes. Br J Haematol 2011; 153: 24–32.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Erdogan B, Facey C, Qualtieri J, Tedesco J, Rinker E, Ben Isett R et al. Diagnostic microRNAs in myelodysplastic syndrome. Exp Hematol 2011; in press.

  38. Dostalova Merkerova M, Krejcik Z, Votavova H, Belickova M, Vasikova A, Cermak J . Distinctive microRNA expression profiles in CD34+ bone marrow cells from patients with myelodysplastic syndrome. Eur J Hum Genet 2011; 19: 313–319.

    Article  PubMed  Google Scholar 

  39. Votavova H, Grmanova M, Dostalova Merkerova M, Belickova M, Vasikova A, Neuwirtova R et al. Differential expression of microRNAs in CD34+ cells of 5q- syndrome. J Hematol Oncol 2010; 4: 1.

    Article  Google Scholar 

  40. Hussein K, Busche G, Muth M, Gohring G, Kreipe H, Bock O . Expression of myelopoiesis-associated microRNA in bone marrow cells of atypical chronic myeloid leukaemia and chronic myelomonocytic leukaemia. Ann Hematol 2010; 90: 307–313.

    Article  PubMed  Google Scholar 

  41. Pons A, Nomdedeu B, Navarro A, Gaya A, Gel B, Diaz T et al. Hematopoiesis-related microRNA expression in myelodysplastic syndromes. Leuk Lymphoma 2009; 50: 1854–1859.

    Article  CAS  PubMed  Google Scholar 

  42. Starczynowski DT, Kuchenbauer F, Argiropoulos B, Sung S, Morin R, Muranyi A et al. Identification of miR-145 and miR-146a as mediators of the 5q- syndrome phenotype. Nat Med 2010; 16: 49–58.

    Article  CAS  PubMed  Google Scholar 

  43. Oliva EN, Nobile F, Iacopino P, Alimena G, Raimondo FD, Palumbo GA et al. Increases in Mirna-145 and Mirna-146a Expression in Patients with IPSS Lower-Risk Myelodysplastic Syndromes and Del(5q) Treated with Lenalidomide. American Society of Hematology: Orlando, FL, 2010.

    Google Scholar 

  44. Kumar M, Narla A, Nonami A, Ball B, Chin C, Chen C et al. Coordinate Loss of a MicroRNA Mir 145 and a Protein-Coding Gene RPS14 Cooperate in the Pathogenesis of 5q- Syndrome. American Society of Hematology: New Orleans, LA, 2009.

    Google Scholar 

  45. Boultwood J, Pellagatti A, Cattan H, Lawrie CH, Giagounidis A, Malcovati L et al. Gene expression profiling of CD34+ cells in patients with the 5q- syndrome. Br J Haematol 2007; 139: 578–589.

    Article  CAS  PubMed  Google Scholar 

  46. Hussein K, Theophile K, Busche G, Schlegelberger B, Gohring G, Kreipe H et al. Significant inverse correlation of microRNA-150/MYB and microRNA-222/p27 in myelodysplastic syndrome. Leuk Res 2010; 34: 328–334.

    Article  CAS  PubMed  Google Scholar 

  47. Metcalf D, Carpinelli MR, Hyland C, Mifsud S, Dirago L, Nicola NA et al. Anomalous megakaryocytopoiesis in mice with mutations in the c-Myb gene. Blood 2005; 105: 3480–3487.

    Article  CAS  PubMed  Google Scholar 

  48. Bousquet M, Quelen C, Rosati R, Mansat-De Mas V, La Starza R, Bastard C et al. Myeloid cell differentiation arrest by miR-125b-1 in myelodysplastic syndrome and acute myeloid leukemia with the t(2;11)(p21;q23) translocation. J Exp Med 2008; 205: 2499–2506.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Starczynowski DT, Vercauteren S, Telenius A, Sung S, Tohyama K, Brooks-Wilson A et al. High-resolution whole genome tiling path array CGH analysis of CD34+ cells from patients with low-risk myelodysplastic syndromes reveals cryptic copy number alterations and predicts overall and leukemia-free survival. Blood 2008; 112: 3412–3424.

    Article  CAS  PubMed  Google Scholar 

  50. Mohamedali A, Gaken J, Twine NA, Ingram W, Westwood N, Lea NC et al. Prevalence and prognostic significance of allelic imbalance by single-nucleotide polymorphism analysis in low-risk myelodysplastic syndromes. Blood 2007; 110: 3365–3373.

    Article  CAS  PubMed  Google Scholar 

  51. Gondek LP, Tiu R, O’Keefe CL, Sekeres MA, Theil KS, Maciejewski JP . Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS/MPD, and MDS-derived AML. Blood 2008; 111: 1534–1542.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Stephenson J, Czepulkowski B, Hirst W, Mufti GJ . Deletion of the acetylcholinesterase locus at 7q22 associated with myelodysplastic syndromes (MDS) and acute myeloid leukaemia (AML). Leuk Res 1996; 20: 235–241.

    Article  CAS  PubMed  Google Scholar 

  53. Le Beau MM, Espinosa III R, Davis EM, Eisenbart JD, Larson RA, Green ED . Cytogenetic and molecular delineation of a region of chromosome 7 commonly deleted in malignant myeloid diseases. Blood 1996; 88: 1930–1935.

    CAS  PubMed  Google Scholar 

  54. Ting AH, McGarvey KM, Baylin SB . The cancer epigenome--components and functional correlates. Genes Dev 2006; 20: 3215–3231.

    Article  CAS  PubMed  Google Scholar 

  55. Ley TJ, Ding L, Walter MJ, McLellan MD, Lamprecht T, Larson DE et al. DNMT3A mutations in acute myeloid leukemia. N Engl J Med 2010; 363: 2424–2433.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Steensma DP, Stone RM . Practical recommendations for hypomethylating agent therapy of patients with myelodysplastic syndromes. Hematol Oncol Clin North Am 2010; 24: 389–406.

    Article  PubMed  Google Scholar 

  57. Issa JP . Epigenetic changes in the myelodysplastic syndrome. Hematol Oncol Clin North Am 2010; 24: 317–330.

    Article  PubMed  PubMed Central  Google Scholar 

  58. Meng Y, Xia Q, Hu J . Promoter Methylation and Decreased Expression of Mir-124 in Myelodysplastic Syndromes. American Society of Hematology: Orlando, FL, 2010.

    Google Scholar 

  59. Dickstein J, Senyuk V, Premanand K, Laricchia-Robbio L, Xu P, Cattaneo F et al. Methylation and silencing of miRNA-124 by EVI1 and self-renewal exhaustion of hematopoietic stem cells in murine myelodysplastic syndrome. Proc Natl Acad Sci USA 2010; 107: 9783–9788.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Jung M, Schaefer A, Steiner I, Kempkensteffen C, Stephan C, Erbersdobler A et al. Robust microRNA stability in degraded RNA preparations from human tissue and cell samples. Clin Chem 2010; 56: 998–1006.

    Article  CAS  PubMed  Google Scholar 

  61. Zuo Z, Calin GA, de Paula HM, Medeiros LJ, Fernandez MH, Shimizu M et al. Circulating microRNAs let-7a and miR-16 predict progression-free survival and overall survival in patients with myelodysplastic syndrome. Blood 2011; 118: 413–415.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  62. Facey C, Isett RB, Tobias J, Baldwin DA, Thompson JE, Carroll M et al. MicroRNA Diagnostic Signature of Myelodysplastic Syndrome. American Society of Hematology: New Orleans, LA, 2009.

    Google Scholar 

  63. List A, Dewald G, Bennett J, Giagounidis A, Raza A, Feldman E et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006; 355: 1456–1465.

    Article  CAS  PubMed  Google Scholar 

  64. List A, Kurtin S, Roe DJ, Buresh A, Mahadevan D, Fuchs D et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 2005; 352: 549–557.

    Article  CAS  PubMed  Google Scholar 

  65. Ebert BL, Pretz J, Bosco J, Chang CY, Tamayo P, Galili N et al. Identification of RPS14 as a 5q- syndrome gene by RNA interference screen. Nature 2008; 451: 335–339.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  66. Barlow JL, Drynan LF, Hewett DR, Holmes LR, Lorenzo-Abalde S, Lane AL et al. A p53-dependent mechanism underlies macrocytic anemia in a mouse model of human 5q- syndrome. Nat Med 2010; 16: 59–66.

    Article  CAS  PubMed  Google Scholar 

  67. Pellagatti A, Jadersten M, Forsblom AM, Cattan H, Christensson B, Emanuelsson EK et al. Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients. Proc Natl Acad Sci USA 2007; 104: 11406–11411.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  68. Wei S, Chen X, Rocha K, Epling-Burnette PK, Djeu JY, Liu Q et al. A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide. Proc Natl Acad Sci USA 2009; 106: 12974–12979.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  69. Venner CP, List A, Nevill TJ, Deeg HJ, Caceres G, Scott BL et al. Induction of Micro RNA-143 and 145 in Pre-Treatment CD34+ Cells From Patients with Myelodysplastic Syndrome (MDS) After in Vitro exposure to Lenalidomide Correlates with Clinical Response in Patients Harboring the Del5q Abnormality. American Society of Hematology: Orlando, FL, 2010.

    Google Scholar 

  70. Gary DJ, Puri N, Won YY . Polymer-based siRNA delivery: perspectives on the fundamental and phenomenological distinctions from polymer-based DNA delivery. J Control Release 2007; 121: 64–73.

    Article  CAS  PubMed  Google Scholar 

  71. Raaijmakers MH, Mukherjee S, Guo S, Zhang S, Kobayashi T, Schoonmaker JA et al. Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia. Nature 2010; 464: 852–857.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  72. Lopez-Villar O, Garcia JL, Sanchez-Guijo FM, Robledo C, Villaron EM, Hernandez-Campo P et al. Both expanded and uncultured mesenchymal stem cells from MDS patients are genomically abnormal, showing a specific genetic profile for the 5q- syndrome. Leukemia 2009; 23: 664–672.

    Article  CAS  PubMed  Google Scholar 

  73. Taganov KD, Boldin MP, Chang KJ, Baltimore D . NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci USA 2006; 103: 12481–12486.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  74. Starczynowski DT, Kuchenbauer F, Wegrzyn J, Rouhi A, Petriv O, Hansen CL et al. MicroRNA-146a disrupts hematopoietic differentiation and survival. Exp Hematol 2010; 39: 167–178, e4.

    Article  PubMed  Google Scholar 

  75. Starczynowski DT, Karsan A . Deregulation of innate immune signaling in myelodysplastic syndromes is associated with deletion of chromosome arm 5q. Cell Cycle 2010; 9: 855–856.

    Article  CAS  PubMed  Google Scholar 

  76. Starczynowski DT, Karsan A . Innate immune signaling in the myelodysplastic syndromes. Hematol Oncol Clin North Am 2010; 24: 343–359.

    Article  PubMed  Google Scholar 

  77. Labbaye C, Spinello I, Quaranta MT, Pelosi E, Pasquini L, Petrucci E et al. A three-step pathway comprising PLZF/miR-146a/CXCR4 controls megakaryopoiesis. Nat Cell Biol 2008; 10: 788–801.

    Article  CAS  PubMed  Google Scholar 

  78. Opalinska JB, Bersenev A, Zhang Z, Schmaier AA, Choi J, Yao Y et al. MicroRNA expression in maturing murine megakaryocytes. Blood 2010; 116: e128–e138.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  79. Zhao JL, Rao DS, Boldin MP, Taganov KD, O’Connell RM, Baltimore D . NF-{kappa}B dysregulation in microRNA-146a-deficient mice drives the development of myeloid malignancies. Proc Natl Acad Sci USA 2011; 108: 9184–9189.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  80. Lu LF, Boldin MP, Chaudhry A, Lin LL, Taganov KD, Hanada T et al. Function of miR-146a in controlling Treg cell-mediated regulation of Th1 responses. Cell 2010; 142: 914–929.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  81. Boldin MP, Taganov KD, Rao DS, Yang L, Zhao JL, Kalwani M et al. miR-146a is a significant brake on autoimmunity, myeloproliferation, and cancer in mice. J Exp Med 2011; 208: 1189–1201.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  82. O’Connell RM, Chaudhuri AA, Rao DS, Gibson WS, Balazs AB, Baltimore D . MicroRNAs enriched in hematopoietic stem cells differentially regulate long-term hematopoietic output. Proc Natl Acad Sci USA 2010; 107: 14235–14240.

    Article  PubMed  PubMed Central  Google Scholar 

  83. Baek D, Villen J, Shin C, Camargo FD, Gygi SP, Bartel DP . The impact of microRNAs on protein output. Nature 2008; 455: 64–71.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

We thank Drs Melinda Varney (CCHMC), Jing Fang (CCHMC) and Mariusz Ratajczak (University of Louisville) for helpful discussions and suggestions. This work was supported by Cincinnati Children's Hospital Medical Center Foundation.

Author information

Authors and Affiliations

  1. Department of Cancer and Cell Biology, College of Medicine, University of Cincinnati, Cincinnati, OH, USA

    G W Rhyasen & D T Starczynowski

  2. Division of Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Research Foundation, Cincinnati, OH, USA

    D T Starczynowski

Authors
  1. G W Rhyasen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D T Starczynowski
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to D T Starczynowski.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rhyasen, G., Starczynowski, D. Deregulation of microRNAs in myelodysplastic syndrome. Leukemia 26, 13–22 (2012). https://doi.org/10.1038/leu.2011.221

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2011.221

Keywords

This article is cited by

Search

Advanced search

Quick links